Skip to main content
Clinical Trials/NCT07759180
NCT07759180CompletedNot Applicable

A Prospective Randomized Controlled Trial of a Sterile Gauze Containing Natural Plant Extracts (Leniben®) for Eyelid Hygiene in Patients With Bilateral Anterior Blepharitis

Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona1 site in 1 country38 target enrollmentStarted: February 2, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
38
Locations
1
Primary Endpoint
Difference in Post-Treatment Eyelid Bacterial Load Adjusted for Baseline

Study Overview

Brief Summary

The goal of this clinical trial is to learn whether a sterile gauze containing natural plant extracts can lower the number of bacteria on the eyelid margin in people with bilateral anterior blepharitis. The study will also evaluate whether the product is safe and well tolerated after a single application.

The main questions it aims to answer are:

  • Does the sterile gauze containing natural plant extracts reduce the bacterial load on the eyelid margin more than a standard sterile gauze?
  • Does the treatment improve eyelid comfort without causing unwanted side effects?

Researchers will compare the study gauze with a sterile gauze without active ingredients. Each participant will receive both treatments: the right eye will be treated with the study gauze, while the left eye will be treated with the control gauze. This allows each participant to serve as their own control.

Participants will:

  • Attend one study visit.
  • Undergo an eye examination to confirm the diagnosis of bilateral anterior blepharitis.
  • Have samples collected from the upper and lower eyelid margins of both eyes before treatment.
  • Receive eyelid cleansing with the assigned gauze for each eye.
  • Have eyelid samples collected again 20 minutes after treatment.
  • Complete a short questionnaire about treatment comfort and tolerability.

The study will compare the change in bacterial growth between the two eyes to determine whether the natural plant-based gauze provides additional microbiological benefits beyond mechanical eyelid cleansing alone. Safety and participant comfort will also be assessed.

Detailed Description

Anterior blepharitis is a chronic inflammatory disorder of the eyelid margin characterized by erythema, scaling, crusting, and ocular discomfort. The condition is frequently associated with increased bacterial colonization of the eyelid margin, particularly by Staphylococcus aureus and coagulase-negative staphylococci, which contribute to chronic inflammation through the production of lipases, proteases, and other virulence factors. Bacterial biofilm formation further promotes microbial persistence and recurrent disease, making eyelid hygiene a fundamental component of long-term management.

Although mechanical cleansing of the eyelid margin is widely recommended, limited clinical evidence is available regarding the immediate microbiological efficacy of sterile eyelid cleansing devices containing natural plant-derived compounds. Leniben® Gauze is a sterile single-use cotton gauze impregnated with sodium hyaluronate, Echinacea angustifolia extract, Ananas sativus extract (bromelain), ammonium glycyrrhizate, and tocopherol. The device is intended to combine the mechanical removal of eyelid debris and microbial biofilm with the moisturizing and soothing properties of its active ingredients.

This prospective, randomized, paired-eye controlled clinical trial is designed to evaluate the microbiological efficacy of Leniben® Gauze in adults with bilateral anterior blepharitis. Each participant serves as his or her own control: the right eye receives treatment with Leniben® Gauze, while the contralateral eye is treated with an identical sterile cotton gauze moistened with sterile saline solution. This paired-eye design minimizes inter-individual variability in eyelid microbiota and allows direct comparison between the active formulation and mechanical cleansing alone.

Microbiological samples are collected from the upper and lower eyelid margins of both eyes immediately before treatment and 20 minutes after the cleansing procedure. Samples are cultured using standard microbiological techniques, and bacterial growth is quantified as colony-forming units (CFU). Changes in bacterial load and bacterial eradication rates are compared between treatments. Participant-reported tolerability and any treatment-related adverse events are also assessed.

The results of this study will provide evidence on the ability of a plant-based sterile eyelid cleansing device to reduce periocular bacterial colonization and may support its use as a non-antibiotic adjunctive strategy for eyelid hygiene in anterior blepharitis and for reducing bacterial burden before ophthalmic procedures.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Masking Description

This is a prospective, randomized, paired-eye controlled trial in which each participant serves as his or her own control. For each participant, one eye was randomly assigned to treatment with Leniben® Gauze containing natural plant extracts, while the contralateral eye was randomly assigned to treatment with an identical sterile cotton gauze moistened with sterile saline. Microbiological outcomes were compared within the same participant, thereby minimizing inter-individual variability in eyelid bacterial colonization and improving the precision of treatment effect estimates.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adults aged 18 years or older.
  • •Clinical diagnosis of bilateral anterior blepharitis confirmed by slit-lamp examination.
  • •Presence in both eyes of eyelid-margin inflammation associated with at least two of the following clinical signs: eyelid-margin hyperemia; eyelash crusting or collarettes; scaling or debris at the base of the eyelashes; lash abnormalities; mucocutaneous inflammation.
  • •Presence of at least one associated symptom, including burning, itching, foreign-body sensation, tearing, or ocular irritation.
  • •Ability and willingness to provide written informed consent.

Exclusion Criteria

  • •Active ocular infection other than anterior blepharitis.
  • •Predominantly posterior blepharitis requiring specific treatment.
  • •Clinically evident Demodex infestation.
  • •Ocular surgery within the previous 3 months.
  • •Contact lens wear.
  • •Use of topical or systemic antibiotics, antiseptics, or corticosteroids within the previous 4 weeks.
  • •Ocular trauma.
  • •Autoimmune disease or immunodeficiency.
  • •Pregnancy or breastfeeding.
  • •Known hypersensitivity to any component of the study products.

Arms & Interventions

Leniben

Experimental

A sterile single-use 100% cotton gauze impregnated with a solution containing sodium hyaluronate, Echinacea angustifolia extract, Ananas sativus extract (bromelain), ammonium glycyrrhizate, and tocopherol.

Intervention: Plant-Based Sterile Eyelid Gauze (Device)

Control

Sham Comparator

A sterile single-use 100% cotton gauze moistened with sterile saline solution and containing no active ingredients.

Intervention: Sterile Cotton Gauze Moistened with Saline Solution (Device)

Outcomes

Primary Outcomes

Difference in Post-Treatment Eyelid Bacterial Load Adjusted for Baseline

Time Frame: Baseline and 20 minutes after a single treatment

Baseline-adjusted difference in total eyelid-margin bacterial load 20 minutes after cleansing between eyes treated with a sterile gauze containing natural plant extracts and contralateral eyes treated with sterile saline-moistened gauze. Total bacterial load is defined as the sum of colony-forming units per milliliter (CFU/mL) of all bacterial species isolated from each eye and analyzed after log₁₀(CFU/mL + 1) transformation.

Secondary Outcomes

  • Culture-Negative Conversion(20 minutes after a single treatment)
  • Percentage Reduction in Eyelid Bacterial Load(Baseline and 20 minutes after a single treatment)
  • Changes in Eyelid Microbiological Profile(Baseline and 20 minutes after a single treatment)
  • Treatment Comfort and Tolerability(Immediately after treatment)
  • Treatment-Related Adverse Events(From treatment administration until completion of the study visit (20 minutes))

Investigators

Sponsor
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mario Troisi

Dr

Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona

Study Sites (1)

Loading locations...

Similar Trials